[Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)].
Marek Lommatzsch(Universitätsmedizin Rostock), Torsten Bauer(Helios Klinikum Emil von Behring), Brit Häcker(German Central Institute for Social Issues), Martin Kolditz(University Hospital Carl Gustav Carus), Hubert Wirtz(Coral Reef Alliance), Klaus F. Rabe(Christian-Albrechts-Universität zu Kiel), Wolfram Windisch(Kliniken der Stadt Köln), Ralf Otto-Knapp, Christian Taube(Ruhrlandklinik), Stavros Konstantinides(Johannes Gutenberg University Mainz), Felix C. Ringshausen(Medizinische Hochschule Hannover), Tobias Welte(Medizinische Hochschule Hannover), Martin Reck(German Center for Lung Research), Hilte Geerdes‐Fenge(Universitätsmedizin Rostock), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), C. Franz Vogelmeier(Philipps University of Marburg), Torsten Blum(MSB Medical School Berlin), Marcus Joest(Lungenklinik Hemer), T. Schaberg, H. Worth(Klinikum Fürth), Jens Gottlieb(Medizinische Hochschule Hannover), F. J. Meyer(München Klinik Bogenhausen), Michael Kreuter(Johannes Gutenberg University Mainz)
Cited by 15
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)
|European Respiratory Journal|2019|1.6k
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
|Journal of Clinical Oncology|2009|1.5k